

Allogeneic hematopoietic cell transplantation for diffuse  
when and how?

Bone Marrow Transplantation

49, 1-7

DOI: [10.1038/bmt.2013.72](https://doi.org/10.1038/bmt.2013.72)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. <i>Blood</i> , 2014, 124, 2354-2361.	0.6	382
3	Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM)â€™s Campath Allogeneic Stem Cell Transplantation for Aggressive Non-Hodgkin Lymphoma: An Analysis of Outcomes from the British Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 483-488.	2.0	5
4	Engraftment syndrome, the Emperorâ€™s new clothes and the artist formerly known as prince. <i>Bone Marrow Transplantation</i> , 2015, 50, 483-484.	1.3	8
5	Antitumor activity of fucoidan against diffuse large B cell lymphoma &lt;it>in vitro&lt;/it> and &lt;it>in vivo&lt;/it>. <i>Acta Biochimica Et Biophysica Sinica</i> , 2015, 47, 925-931.	0.9	37
6	Raiders of the lost mark â€™ endothelial cells and their role in transplantation for hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2016, 57, 2752-2762.	0.6	8
7	Allogeneic transplantation provides durable remission in a subset of <scp>DLBCL</scp> patients relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2016, 174, 235-248.	1.2	115
8	Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1543-1551.	2.0	42
9	Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016, 38, 314-319.	0.7	1
10	Prognostic factors in patients with relapsed or refractory diffuse large B-cell lymphoma who underwent autologous stem-cell transplantation. <i>Journal of Hematopoietic Cell Transplantation</i> , 2016, 5, 93-101.	0.1	0
11	Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas. <i>Hematological Oncology</i> , 2017, 35, 17-24.	0.8	9
12	Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review. <i>Bone Marrow Transplantation</i> , 2017, 52, 941-949.	1.3	22
13	Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 145-151.	0.2	9
14	Profiles of pro-inflammatory cytokines in allogenic stem cell transplantation with post-transplant cyclophosphamide. <i>Cytokine</i> , 2017, 99, 148-153.	1.4	12
15	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2531-2544.	13.9	3,865
16	Hematopoietic cell transplants for Hodgkin lymphoma. , 0, , 361-371.		0
17	Hematopoietic cell transplants for aggressive B-cell lymphomas. , 0, , 417-427.		0
18	SLE and Non-Hodgkinâ€™s Lymphoma: A Case Series and Review of the Literature. <i>Case Reports in Rheumatology</i> , 2017, 2017, 1-7.	0.2	10
19	Utility of routine surveillance imaging for diffuse large B-cell lymphoma post autologous transplant: A single center experience. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 135-141.	0.6	1

#	ARTICLE	IF	CITATIONS
20	Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1133-1142.	0.6	23
21	Hematopoietic Stem Cell Transplantation in the Era of Engineered Cell Therapy. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 484-493.	1.2	7
22	Double-hit and double-expressor B-cell lymphomas: Current treatment strategies and impact of hematopoietic cell transplantation. <i>Advances in Cell and Gene Therapy</i> , 2018, 1, e13.	0.6	2
23	Allogeneic Transplant for Non-Hodgkin Lymphoma. , 2019, , 209-229.		0
24	Outcomes of allogeneic stem cell transplantation for DLBCL: a multi-center study from the Kyoto Stem Cell Transplantation Group. <i>Annals of Hematology</i> , 2019, 98, 2815-2823.	0.8	11
25	Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim. <i>BioDrugs</i> , 2019, 33, 635-645.	2.2	9
26	Parsaclisib, a potent and highly selective PI3K $\hat{\nu}$ inhibitor, in patients with relapsed or refractory B-cell malignancies. <i>Blood</i> , 2019, 133, 1742-1752.	0.6	84
27	Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era. <i>Annals of Hematology</i> , 2021, 100, 2253-2260.	0.8	9
28	Targeted In $\hat{\nu}$ Vivo Delivery of NF- $\hat{\nu}$ B Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy. <i>Molecular Therapy</i> , 2021, 29, 1214-1225.	3.7	6
29	Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine. <i>International Journal of Hematology</i> , 2021, 114, 544-553.	0.7	6
32	Paroxysmal Nocturnal Hemoglobinuria in Patients with Aplastic Anemia: Challenges, Characteristics, and Analysis of Clinical Experience. <i>Klinicheskaya Onkologematologiya/Clinical Oncohematology</i> , 2019, 12, 319-328.	0.1	3
33	Hematopoietic Progenitor Cells, Apheresis and Therapeutic Cells, T-Cells Collection: Instrumentation, Operating Parameters, and Troubleshooting. <i>Advances and Controversies in Hematopoietic Transplantation and Cell Therapy</i> , 2020, , 81-100.	0.0	1
34	A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection. <i>Bone Marrow Transplantation</i> , 2022, 57, 176-182.	1.3	1
35	Aplastische An $\hat{\nu}$ mien. , 2020, , 359-374.		0
36	Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Endocrinology</i> , 2022, 13, 846357.	1.5	5
37	Outcomes of allogeneic hematopoietic stem cell transplantation in secondary central nervous system lymphoma: a case series. <i>Leukemia and Lymphoma</i> , 2023, 64, 507-510.	0.6	0
38	Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 0, , .	0.8	0
39	Relapsed or refractory large B $\hat{\nu}$ cell lymphoma after chimeric antigen receptor T $\hat{\nu}$ cell therapy: Current challenges and therapeutic options. <i>British Journal of Haematology</i> , 2023, 201, 15-24.	1.2	3

#	ARTICLE	IF	CITATIONS
40	Safety of CAR-T Cell Therapy in Patients With Renal Failure/Acute Kidney Injury: Focused Review. Clinical Hematology International, 2023, 5, 122-129.	0.7	4